Clinically meaningful improvements in cutaneous lesions and quality of life measures in patients with atopic dermatitis with greater pruritus reductions after treatment with 60 mg nemolizumab subcutaneously every 4 weeks: subgroup analysis from a phase 3, randomized, controlled trial

• Asıl Yazarlar: Kenji Kabashima (Yazar), Takayo Matsumura (Yazar), Yoshiteru Hayakawa (Yazar), Makoto Kawashima (Yazar), for the Nemolizumab-JP01 Study Group (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: Taylor & Francis Group, 2023-12-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

Background Data from the Japanese phase 3 Nemolizumab-JP01 study (JapicCTI-173740) found that nemolizumab in combination with topical treatments reduced pruritus associated with atopic dermatitis inadequately controlled with current therapies. Methods This post-hoc analysis examined associations bet...